Medical/Pharmaceuticals
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
2022-10-11 19:00
1093
Integrating Fitbit & MindFi App into Daily Lifestyle Leads to Significant Improvements in Teachers' Mental Wellness - Singapore Study
SINGAPORE, Oct. 11, 2022 /PRNewswire/ -- Regular use of a mental wellness app solution combined with Fitbit wearable devices to track activity and sleep can have a positive impact on users' physical and mental health, according to a new pilot study involvingSingapore teachers. After a challeng...
2022-10-11 17:13
1836
Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days to 150 days LEIDEN...
2022-10-11 13:00
1469
Anti-Oxidant Extracts from Young Durians - Potential Value-Added Cosmetics from Agricultural Waste by Chula
Chula Faculty of Science researchers find young durian extracts to have as high anti-oxidants as vitamin C and aim to produce skin care products that add value to agricultural waste. BANGKOK, Oct. 11, 2022 /PRNewswire/ -- The durian has been called the king of fruits, andThailand's vital cash cr...
2022-10-11 10:55
2480
Translumina further strengthens senior leadership to drive next phase of growth
NEW DELHI, Oct. 10, 2022 /PRNewswire/ -- Translumina - a global developer and manufacturer of innovative cardiovascular medical devices, implants and access products - appointedIndranil Mukherjee as Group CEO and Armin Kiser as Managing Director and Chief Operating Officer for the company'sEurope...
2022-10-10 21:35
1725
MAYBELLINE NY LAUNCHES FREE MENTAL HEALTH TRAINING IN COLLEGES
Brave Talk is a global college training program designed in partnership with mental health experts to give students the tools to support those around them experiencing anxiety or depression NEW YORK, Oct. 10, 2022 /PRNewswire/ -- More than half of first-year college students (54%) frequently ...
2022-10-10 21:00
2022
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina has approved ...
2022-10-10 20:00
2372
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with elevated pTau biomarker with once daily, 10 mg, oral therapy SYDNEY, Oct. 10, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alz...
2022-10-10 20:00
1332
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
* Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology. * Pierre Fabre strengthens its activities in the field of rare diseases, and more specifically pediatric ones. * This partnership paves th...
2022-10-10 15:00
1605
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...
2022-10-10 08:23
2568
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...
2022-10-10 08:20
2078
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral ...
2022-10-10 08:10
1776
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial ev...
2022-10-10 08:00
2002
WuXi Biologics Co., Ltd. Removed from Unverified List
WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U....
2022-10-10 07:55
3184
Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma, new study presented at UEG Week suggests
VIENNA, Oct. 9, 2022 /PRNewswire/ -- Eating a Mediterranean diet, rich in fibre, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 h...
2022-10-09 06:01
1885
Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA
* Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. * It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- ...
2022-10-08 11:00
1800
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...
2022-10-08 10:43
1951
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections
SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, annou...
2022-10-08 08:00
2418
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
1649
Raffles Medical Group and NalaGenetics Provide Pre-emptive Genetic Testing for Adverse Drug Reactions
* Raffles is the first hospital in Singapore to provide pre-emptive pharmacogenomics testing protocol * Aims to reduce side effects due to inappropriate medications SINGAPORE, Oct. 7, 2022 /PRNewswire/ -- Raffles Medical Group (RMG) is collaborating with biotech start-up NalaGenetics to offer...
2022-10-07 17:22
2475
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 302 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8752
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
8117
Where does China's production capacity come from?
2024-05-10 12:01
7954
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4980